Keratin 19 Antibody BA17 / Cytokeratin 19 Monoclonal Antibody [clone BA17] (V3137)

Description

Keratin 19 Antibody BA17 / Cytokeratin 19 Monoclonal Antibody recognizes the rod domain of human keratin 19, a type I intermediate filament protein encoded by the KRT19 gene. Clone BA17 is an established monoclonal antibody with an extensive history in epithelial and carcinoma research. Its recognition of the KRT19 rod domain provides a molecular distinction from antibodies directed against other regions of the protein. Keratin 19 is structurally unusual among type I keratins because it lacks the extended C-terminal tail domain found in many other family members.

KRT19 contributes to epithelial cytoskeletal organization by forming intermediate filament networks with compatible type II keratins, particularly keratin 8. These networks help maintain cellular architecture and mechanical stability in tissues exposed to physical stress. KRT19 is expressed in numerous simple, glandular, and ductal epithelia, including mammary ducts, biliary epithelial cells, pancreatic ducts, and gastrointestinal tissues. The Cytokeratin 19 Monoclonal Antibody is therefore relevant to investigations of epithelial differentiation, tissue organization, and cellular lineage identity.

In cancer research, KRT19 is widely investigated as a marker of epithelial differentiation. Its expression is frequently retained in adenocarcinomas of the breast, colon, stomach, pancreas, and hepatobiliary system. Keratin 19 Antibody BA17 has particular relevance to studies examining the distribution of keratin-positive tumor cells within complex tissue architecture. In thyroid pathology, CK19 expression is commonly associated with papillary thyroid carcinoma, although positivity also occurs in other thyroid lesions and must be interpreted alongside morphology and complementary markers.

Clone BA17 has a substantial publication history, making its specific identity valuable when comparing antibody-based findings across established research methods. Its recognition of the KRT19 rod domain provides an additional consideration for experimental reproducibility and clone selection. However, recognition of a defined protein region does not independently establish the absence of cross-reactivity with related keratins. Researchers should consider tissue context and appropriate controls when interpreting immunoreactivity.

NSJ Bioreagents provides this mouse monoclonal antibody for investigating KRT19 expression in human epithelial tissues and carcinoma models. The Cytokeratin 19 Monoclonal Antibody supports research into epithelial differentiation, intermediate filament organization, and carcinoma-associated cytoskeletal expression.

For additional KRT19 detection options, see our anchor Cytokeratin 19 Antibody KRT19/799 | CK19 | V2678.

Application Notes

The optimal dilution of the Keratin 19 Antibody BA17 / Cytokeratin 19 Monoclonal Antibody for each application should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in pH 9 10mM Tris with 1mM EDTA for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Immunogen

Human mammary epithelial organoids were used as the immunogen for this Keratin 19 antibody.

Storage

Store the Keratin 19 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Alternate Names

Cytokeratin 19 antibody, CK19 antibody, KRT19 antibody, K19 antibody, Cytokeratin-19 antibody, Type I Cytoskeletal Keratin 19 antibody